Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of U3-1287 with trastuzumab plus paclitaxel in HER2-positive metastatic breast cancer
jRCT2080221730Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of patritumab in HER2-enriched breast cancer (HER2+), sponsored by Daiichi Sankyo Co., Ltd.
02
Drugs
patritumab
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on jRCT2080221730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221730.